222 related articles for article (PubMed ID: 16468986)
1. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
Hu G; Lin G; Wang M; Dick L; Xu RM; Nathan C; Li H
Mol Microbiol; 2006 Mar; 59(5):1417-28. PubMed ID: 16468986
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity.
Lin G; Hu G; Tsu C; Kunes YZ; Li H; Dick L; Parsons T; Li P; Chen Z; Zwickl P; Weich N; Nathan C
Mol Microbiol; 2006 Mar; 59(5):1405-16. PubMed ID: 16468985
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.
Hsu HC; Singh PK; Fan H; Wang R; Sukenick G; Nathan C; Lin G; Li H
Biochemistry; 2017 Jan; 56(1):324-333. PubMed ID: 27976853
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
[TBL] [Abstract][Full Text] [Related]
5. Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.
Lin G; Tsu C; Dick L; Zhou XK; Nathan C
J Biol Chem; 2008 Dec; 283(49):34423-31. PubMed ID: 18829465
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the assembly and gate closure mechanisms of the Mycobacterium tuberculosis 20S proteasome.
Li D; Li H; Wang T; Pan H; Lin G; Li H
EMBO J; 2010 Jun; 29(12):2037-47. PubMed ID: 20461058
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
8. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
Huber EM; Heinemeyer W; Groll M
Structure; 2015 Feb; 23(2):407-17. PubMed ID: 25599643
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
Groll M; Berkers CR; Ploegh HL; Ovaa H
Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
12. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
[TBL] [Abstract][Full Text] [Related]
13. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
Pekol T; Daniels JS; Labutti J; Parsons I; Nix D; Baronas E; Hsieh F; Gan LS; Miwa G
Drug Metab Dispos; 2005 Jun; 33(6):771-7. PubMed ID: 15764713
[TBL] [Abstract][Full Text] [Related]
14. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
15. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
[TBL] [Abstract][Full Text] [Related]
16. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
Xie SC; Gillett DL; Spillman NJ; Tsu C; Luth MR; Ottilie S; Duffy S; Gould AE; Hales P; Seager BA; Charron CL; Bruzzese F; Yang X; Zhao X; Huang SC; Hutton CA; Burrows JN; Winzeler EA; Avery VM; Dick LR; Tilley L
J Med Chem; 2018 Nov; 61(22):10053-10066. PubMed ID: 30373366
[TBL] [Abstract][Full Text] [Related]
17. Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif.
Stein ML; Cui H; Beck P; Dubiella C; Voss C; Krüger A; Schmidt B; Groll M
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1679-83. PubMed ID: 24403024
[TBL] [Abstract][Full Text] [Related]
18. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
19. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
20. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]